摘要
目的为了探讨胰高血糖素样肽-1(glucagon-like peptide-1,GLP-1)受体激动剂对糖尿病患者的成骨细胞和破骨细胞的影响。方法利用小鼠成骨细胞MC3T3-E1和小鼠单核巨噬细胞RAW264.7模拟成骨细胞和破骨细胞。在高糖培养基中分别加入不同浓度的艾塞那肽孵育72 h,利用RT-qPCR技术分别检测成骨细胞MC3T3-E1中GLP1-R、ALP、LRP-5和破骨细胞RAW 264.7中GLP1-R、Cathespin K的表达情况。结果艾塞那肽诱导成骨细胞MC3T3-E1细胞中GLP-1R、ALP、LRP-5基因的表达显著升高,而明显抑制破骨细胞RAW 264.7中GLP1-R、Cathespin K的表达。结论GLP-1受体激动剂艾塞那肽可能通过影响成骨细胞及破骨细胞的分化,从而对糖尿病引起的骨质疏松起到一定程度的改善。
Objective To explore the effect of glucagon-like peptide-1(GLP-1)receptor agonist on osteoblast and osteoclast induced by diabetes mellitus.Methods Murine osteoblast MC3T3-E1 and mononuclear macrophage RAW264.7 were treated to simulate osteoblasts and osteoclasts.Following a 72 h different concentrations of Exenatide-4 incubation in high glucose medium,RT-qPCR was used for detecting the expressions of GLP1-R,ALP and LRP-5 in osteoblast MC3T3-E1 and GlP1-R,Cathespin K in osteoclast RAW 264.7.Results Exenatide-4 significantly increased the expression of GLP-1R,ALP and LRP-5 in MC3T3-E1 while dramatically decreasing GLP1-R and Cathespin K in RAW 264.7.Conclusion Exenatide-4,a GLP-1 receptor agonist,may reduce diabetes-related osteoporosis through affecting the differentiation of osteoblasts and osteoclasts.
作者
张条条
周心禾
ZHANG Tiaotiao;ZHOU Xinhe(The Second Affiliated Hospital of Wenzhou Medical University,Wenzhou 325000,China)
出处
《中国骨质疏松杂志》
CAS
CSCD
北大核心
2023年第4期493-496,502,共5页
Chinese Journal of Osteoporosis
基金
肠促胰岛激素对骨代谢及骨质疏松症的作用及机制的研究(2019330727)。
